Literature DB >> 14563462

Inverse correlation of each functional status scale of the SF-36 with degree of disease activity in systemic lupus erythematosus (m-SLAM).

Jihan Saba1, Robert J Quinet, William E Davis, Marie Krousel-Wood, Richard Chambers, Natalie Gomez, Leonard Serebro, Priya Nair.   

Abstract

OBJECTIVES: To compare systemic lupus erythematosus (SLE) disease activity measured by a modified Systemic Lupus Activity Measure (m-SLAM) with functional/health status measured by the SF-36 questionnaire. PATIENTS AND METHODS: m-SLAM and SF-36 scores were obtained on 71 SLE patients during 242 clinic visits over 15 months. Patients were stratified into disease activity groups (m-SLAM <2 = remission; 2-4 = mild; 4-6 = moderate; >6 = severe). Mean SF-36 group scores were compared by analysis of variance (ANOVA).
RESULTS: Two hundred and nineteen m-SLAM and SF-36 scores were completed. The disease activity groups correlated inversely with the SF-36 scores in all eight subscales, i.e. the patients' perceived health, as assessed by the SF-36, correlated with their disease activity level as measured by the m-SLAM. Inverse correlation of SLAM activity groups with all eight SF-36 subscales was highly statistically significant.
CONCLUSION: The significant inverse correlation of the m-SLAM with all domains of the SF-36 in this study provides potentially useful information for evaluating patients with SLE.

Entities:  

Mesh:

Year:  2003        PMID: 14563462     DOI: 10.1016/s1297-319x(03)00065-4

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  9 in total

1.  Health-related quality of life and employment among persons with systemic lupus erythematosus.

Authors:  Jinoos Yazdany; Edward Yelin
Journal:  Rheum Dis Clin North Am       Date:  2010-02       Impact factor: 2.670

2.  Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time.

Authors:  G S Alarcón; J Calvo-Alén; G McGwin; A G Uribe; S M A Toloza; J M Roseman; M Fernández; B J Fessler; L M Vilá; C Ahn; F K Tan; J D Reveille
Journal:  Ann Rheum Dis       Date:  2006-09       Impact factor: 19.103

3.  Predictors of self-reported health-related quality of life in systemic lupus erythematosus.

Authors:  Adnan N Kiani; Vibeke Strand; Hong Fang; Jawali Jaranilla; Michelle Petri
Journal:  Rheumatology (Oxford)       Date:  2013-05-16       Impact factor: 7.580

4.  Intravenous immunoglobulin treatment of the post-polio syndrome: sustained effects on quality of life variables and cytokine expression after one year follow up.

Authors:  Henrik Gonzalez; Mohsen Khademi; Kristian Borg; Tomas Olsson
Journal:  J Neuroinflammation       Date:  2012-07-09       Impact factor: 8.322

5.  Quality of life and satisfaction with life in SLE patients-the importance of clinical manifestations.

Authors:  Lilianna Kulczycka; Anna Sysa-Jedrzejowska; Ewa Robak
Journal:  Clin Rheumatol       Date:  2010-06-09       Impact factor: 2.980

6.  Cultural and quality-of-life considerations when administering corticosteroids as a therapeutic strategy for African American women living with systemic lupus erythematosus.

Authors:  Dorcey L Applyrs; Edith M Williams; Trevor D Faith; Diane L Kamen; Elizabeth Vazques; Janine M Jurkowski
Journal:  Patient Prefer Adherence       Date:  2018-06-12       Impact factor: 2.711

7.  Severe flares are associated with a poorer health-related quality of life (HRQoL) in patients with SLE: data from the Almenara Lupus Cohort.

Authors:  Manuel Francisco Ugarte-Gil; Rocio Violeta Gamboa-Cardenas; Cristina Reátegui-Sokolova; Victor Román Pimentel-Quiroz; Mariela Medina; Claudia Elera-Fitzcarrald; Francisco Zevallos; Cesar Augusto Pastor-Asurza; Federico Zazzetti; Chetan S Karyekar; Graciela S Alarcón; Risto Alfredo Perich-Campos
Journal:  Lupus Sci Med       Date:  2022-03

8.  Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases.

Authors:  C P Denton; J E Pope; H-H Peter; A Gabrielli; A Boonstra; F H J van den Hoogen; G Riemekasten; S De Vita; A Morganti; M Dölberg; O Berkani; L Guillevin
Journal:  Ann Rheum Dis       Date:  2007-11-30       Impact factor: 19.103

9.  Patient-reported outcome measures for use in clinical trials of SLE: a review.

Authors:  Zara Izadi; Julie Gandrup; Patricia P Katz; Jinoos Yazdany
Journal:  Lupus Sci Med       Date:  2018-08-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.